



PRESS RELEASE

Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022

Heidelberg, Germany, March 24, 2022 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2021 results and corporate update on Thursday, March 31, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference conference ID 6590614 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of the company’s website at <https://www.affimed.com/investors/>. A replay of the call will be archived on Affimed’s website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK[®] platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK[®] platform predictably generates customized innate cell engager (ICE[®]) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE[®]. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact

Alexander Fudukidis

Director, Head of Investor Relations

E-Mail: a.fudukidis@affimed.com

Tel.: +1 (917) 436-8102